Certified into the record
The exact text we saved
This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.
TRUVACE RECORD VERSION record: TRV-2026-1229 version: 1 kind: certified reason: Certified into the record timestamp: 2026-10-01T06:54:31.424131Z status: published lens: g_space sector: health headline: Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI dek: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational... gain_title: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration. problem_title: (none) trace_subject: (none) gain_reading: Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration. gain_evidence: design and optimize novel enzyme therapies for BioMarin's pipeline | Profluent announced a collaboration with BioMarin Pharmaceutical Inc. problem_reading: (none) problem_evidence: (none) quick_read: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline, with Profluent applying its foundational technology under the agreement. The partnership illustrates use of AI-driven protein design in pharmaceutical development, but the supplied text does not detail specific targets, timelines, performance results, or clinical outcomes, leaving efficacy and translational impact uncertain. limitation: tag: Evidence-backed gain key_points: Profluent announced a collaboration with BioMarin Pharmaceutical Inc. | The stated goal is to design and optimize novel enzyme therapies for BioMarin's pipeline. | Under the agreement Profluent will apply its foundational AI technology to the effort. rundown: On September 30, 2026, Profluent announced a collaboration with BioMarin Pharmaceutical Inc. focused on novel enzyme therapies. The agreement positions Profluent to apply its foundational platform to design and optimization work intended to support BioMarin's pipeline. sources: - journalism | MarketScreener | https://www.marketscreener.com/news/profluent-and-biomarin-pharmaceutical-inc-partner-to-design-novel-medicines-using-ai-ce785ad3d88bf623 | 2026-09-30 prev: 0000000000000000000000000000000000000000000000000000000000000000
- SHA-256 hash
- 8507a350b89fd66b3a9cca5d7d2fc9cf31c7704f64c688898ed83b06a23bf708
- Previous version’s hash
- 0000000000000000000000000000000000000000000000000000000000000000
How to check it yourself, without trusting this page
Download any version from /api/record/TRV-2026-1229 and hash its canonical field yourself, for example with shasum -a 256. You should get its content_hash. Each version’s text also ends with prev:and the hash of the version before it (version 1 points to 64 zeros). If anyone had changed a single character of any version after it was saved, those hashes wouldn’t line up.
ace